Investigation of dacomitinib on reducing cell necrosis and enhancing cell apoptosis in C6 glioma rat model by MRI.
Ontology highlight
ABSTRACT: BACKGROUND:Glioma is one of the most epidemic and obstinate types of cancer in the central nervous system (CNS) with poor survival rate. Dacomitinib inhibited cell viability and proliferation of epidermal growth factor receptor (EGFR)-amplified glioma. In the present study, the regional effects of Dacomitinib on tumor necrosis was investigated. METHODS:A C6 rat glioma model was evaluated using proton magnetic resonance spectroscopy (1H-MRS), diffusion weighted imaging (DWI), and morphological T2-weighted imaging (T2W). The effects of Dacomitinib on glioma cells were investigated using methods of immunohistochemistry and Hematoxylin and Eosin (H&E) staining. RESULTS:The obtained data indicated that metabolite ratios were significantly decreased (all P<0.05) in the Dacomitinib-treated group compared with C6 glioma control group. The ADC value of necrotic core in Dacomitinib group was significantly lower than that in control group. In addition, the expression of Ki-67 in Dacomitinib-treated group (50.32 ± 5.61) was significantly lower than that in control group (P<0.05). The apoptotic index (AI) (28.01 ± 2.37) in Dacomitinib-treated group was significantly higher than that in control group (11.58 ± 3.17). CONCLUSION:The results demonstrated that the Dacomitinib could suppress glioma cell necrosis and proliferation.
SUBMITTER: Chen WS
PROVIDER: S-EPMC6400661 | biostudies-literature | 2019 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA